title: [Therapeutic options for nonalcoholic fatty liver disease and steatohepatitis].
abstract: Nonalcoholic fatty liver disease (NAFLD) is increasingly recognized as one of the most common causes of chronic liver damage in the western world. It is strongly associated with insulin resistance, obesity and other features of the metabolic syndrome. The entity NAFLD embraces a clinical spectrum from benign steatosis over steatohepatitis to hepatic cirrhosis with its complications liver failure and hepatocellular carcinoma. Treatment is currently based on prescriptive diet and physical exercise. A well-defined pharmacotherapy of NAFLD still remains to be established due to the lack of randomized, controlled trials. Yet, for several drugs such as Metformin and Thiazolidinediones, smaller trials report promising results.
authors.affiliation: Medizinische Klinik I, Universitätsklinikum Hamburg-Eppendorf, Martinistrasse 52, 20246 Hamburg. jkluwe@uke.uni-hamburg.de
authors.forename: J
authors.initials: J
authors.lastname: Kluwe
authors.forename: A W
authors.initials: AW
authors.lastname: Lohse
mesh_terms: D004035:Diet Therapy / Q000379:methods*; D005081:Exercise Therapy / Q000379:methods*; D005234:Fatty Liver / Q000150:complications / Q000628:therapy*; D005235:Fatty Liver, Alcoholic / Q000628:therapy; D006801:Humans; D008103:Liver Cirrhosis / Q000209:etiology / Q000517:prevention & control*; D017093:Liver Failure / Q000209:etiology / Q000517:prevention & control*; D008687:Metformin / Q000627:therapeutic use*; D017410:Practice Guidelines as Topic; D010818:Practice Patterns, Physicians'; D045162:Thiazolidinediones / Q000627:therapeutic use*
chemical_list: D045162:Thiazolidinediones; D008687:Metformin